ImmunoTargets and Therapy (Aug 2021)
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Abstract
Reyisa Bughda, Paraskevi Dimou, Reena R D’Souza, Astero Klampatsa Division of Cancer Therapeutics, The Institute of Cancer Research, London, UKCorrespondence: Astero KlampatsaThoracic Oncology Immunotherapy Group, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UKTel +44 208 722 4090Email [email protected]: Fibroblast activation protein (FAP) is a membrane protease that is highly expressed by cancer-associated fibroblasts (CAFs). FAP can modulate the tumor microenvironment (TME) by remodeling the extracellular matrix (ECM), and its overexpression on CAFs is associated with poor prognosis in various cancers. The TME is in part accountable for the limited efficacy of chimeric antigen receptor (CAR)-T cell therapy in treatment of solid tumors. Targeting FAP with CAR-T cells is one of the strategies being researched to overcome the challenges in the TME. This review describes the role of FAP in the TME and its potential as a target in CAR-T cell immunotherapy, summarizes the preclinical studies and clinical trials of anti-FAP-CAR-T cells to date, and reviews possible optimizations to augment their cytotoxic efficiency in solid tumors.Keywords: CAR T-cells, immunotherapy, tumor microenvironment, fibroblasts, fibroblast-activating-protein, solid tumors, stroma
